RenovoRx, Inc.
No SEC Form 4 filings for $RNXT in the last 30 days.
See all $RNXT insider activity →RenovoRx (RNXT) regained Nasdaq compliance after its stock maintained a $1 minimum bid for 10 days. The company reported Q2 revenue of $909,000, expanded its cancer center customer base, and completed enrollment in its Phase 3 TIGeR-PaC trial. RNXT stock closed at $1.32, down 3.77% in pre-market trading.
RenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.
RenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.
Over the past 7 days, alphai's AI scored 1 news story mentioning RNXT (RenovoRx, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent RNXT coverage spans corporate actions, earnings and technology.
Compliance restores listing eligibility and may stabilize share price.
Guidance upgrade plus Phase III enrollment completion reduces near-term uncertainty on development timeline, but cash burn and runway remain key risk.
The call provides fresh operating and clinical-program milestones plus updated revenue guidance, which can re-rate near-term execution risk and cash runway expectations.
Enrollment completion de-risks trial execution, but the key readout remains pending until 2027 after the required 86 events.
This is a corporate-governance/compensation-plan vote filing; it can affect dilution expectations and near-term sentiment but lacks deal/earnings/clinical catalysts in the text.
alphai scores every news story that mentions RNXT with an AI model for sentiment and relevance, and aggregates insider trades from RenovoRx, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
RenovoRx (RNXT) regained Nasdaq compliance after its stock maintained a $1 minimum bid for 10 days. The company reported Q2 revenue of $909,000, expanded its cancer center customer base, and completed enrollment in its Phase 3 TIGeR-PaC trial. RNXT stock closed at $1.32, down 3.77% in pre-market trading.
1 min readRenovoRx (NASDAQ:RNXT) reported Q2 gross profit of $766,000 and ~84% gross margin. Operating loss was ~$3.4M and net loss per share was $0.06. Cash fell to ~$9.5M at June 30. The company narrowed FY2026 revenue guidance to $3.75M-$4.25M and expects cash-flow break-even in Q4 2027. Phase III TIGeR-PaC enrollment is complete; initial data expected H2 2027.
6 min readRenovoRx (RNXT) reported Q2 2026 revenue of $909,000, up 115% year over year, and raised full-year 2026 guidance to $3.75 million to $4.25 million. The company said it completed Phase III TIGeR-PaC enrollment, had 78 survival events vs 86 required, and expects initial results in H2 2027. Cash was $9.5 million at June 30, 2026.
6 min readRenovoRx (Nasdaq: RNXT) said it has completed enrollment in its Phase III TIGeR-PaC trial for locally advanced pancreatic cancer. Trial enrollment is closing as of Aug. 7, 2026, with completion expected in 1H 2027 after 86 deaths events, and 78 events reported as of Aug. 11. Initial top-line data is expected in 2H 2027; primary endpoint is overall survival.
2 min readRenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. EX-10.1 2 ex10-1.htm EX-10.1 Exhibit 10.1 RENOVORX, INC. 2021 OMNIBUS EQUITY INCENTIVE PLAN (as amended on April 16, 2026) Section 1. Purpose of Plan. The name of the Plan is the RenovoRx, Inc. 2021 Omnibus Equity Incentive Plan (the “ Plan ”). The purposes of the Plan are to (i)
2 min readRenovoRx said the FDA granted orphan drug designation for oxaliplatin to treat pancreatic cancer. The company said it is its second such designation in pancreatic cancer and third overall, supporting its RenovoCath targeted intra-arterial delivery approach. RenovoRx previously received ODD for intra-arterial gemcitabine via RenovoCath. In pre-market trading, RNXT was $0.93.
3 min readRenovoRx (Nasdaq: RNXT) said the FDA granted orphan drug designation for oxaliplatin to treat pancreatic cancer, under Section 526. The company said the designation is its second in pancreatic cancer and third overall, and would provide seven years of market exclusivity plus a 25% tax credit on qualified clinical research and an FDA application fee waiver. RenovoRx is also advancing its Phase III TIGeR-PaC trial and commercializing RenovoCath.
4 min readRenovoRx said a Phase III TIGeR-PaC PK/pharmacodynamic sub-study abstract was published for the 2026 ASCO meeting. The study in 16 patients compared intra-arterial gemcitabine via its TAMP/RenovoCath system (IAG) versus IV gemcitabine, reporting lower systemic gemcitabine and higher inactive metabolite levels, with a correlation to reduced CA 19-9. The company expects full enrollment in June 2026 and final readout mid-to-late 2027.
4 min readRenovoRx, Inc. (RNXT) has issued its 2026 proxy statement detailing proposals for its Annual Meeting on June 30, 2026. Stockholders will vote on electing six directors, increasing the shares available under the 2021 Omnibus Equity Incentive Plan by 2,000,000 (4.4% of total outstanding shares), and ratifying Frank, Rimerman + Co. LLP as the independent registered public accounting firm for 2026. The proxy also outlines executive compensation for 2025, with CEO Shaun R. Bagai receiving over $1.2 million, and provides details on the company's board structure, committee responsibilities, and director independence.
3 min readRenovoRx reported full-year 2025 revenue of $1.1 million for its RenovoCath device, a significant increase from 2024, with 12 U.S. cancer centers actively utilizing the device and 21 more evaluating it. The company's Phase III TIGeR-PaC trial is on track for enrollment completion by mid-2026, with final data anticipated in 2027. RenovoRx also strengthened its financial position with a $10 million private placement, bringing its cash on hand to approximately $13 million.
4 min read
